Pfizer, tariffs Bourla and manufacturing

Pfizer could use existing US manufacturing to counter potential tariff hit
By Christy Santhosh (Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the United States, if required, as the Trump administration threatens numerous tariffs on imported goods.
Pfizer Prepared to Reshore Manufacturing if Trump Makes Good on Tariff Threats
Eli Lilly also responded to the President's tariff warnings by investing $27 billion to construct four manufacturing facilities across the U.S. in five years.
Pfizer CEO says he's prepared to shift manufacturing to the U.S. amid tariff threats
CEO Albert Bourla said on Monday that the drugmaker could move some of its overseas manufacturing to its U.S. plants if necessary, as the Trump administration considers imposing tariffs on pharmaceuticals.
Pfizer's CEO says he's got a plan to deal with Trump's tariffs — move overseas drug manufacturing to the US
"I was expecting him probably to win. It was very big win," Pfizer's CEO Albert Bourla said of President Donald Trump's election victory.
Pfizer could use existing U.S. production to counter tariff hit, Reuters reports
Pfizer (PFE) may move overseas manufacturing to its existing plants in the U.S., if required, as the Trump administration threatens numerous
Pfizer could shift overseas production to US if Trump's pharma tariffs take hold, CEO says
As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert Bourla, Ph.D., outlined one potential response by his company if pharmaceut | Pfizer’s local manufacturing setup is already well positioned in the U.
Pfizer may soon move its overseas manufacturing to United States to counter potential tariff hit
Pfizer CEO Albert Bourla on Monday said that the company might move overseas manufacturing to its existing plants in the United States. The plan comes as the Trump administration
Pfizer's Strategic Manufacturing Shift Amidst Tariff Threats
Pfizer CEO Albert Bourla announced the possibility of shifting overseas manufacturing to U.S. plants. This response is due to the Trump administration's tariff threats on imported goods. Bourla mentioned their U.
Pfizer may move outside manufacturing plants to US: CEO amid tariff threats
The US president has imposed a 10 per cent tariff across all Chinese imports into the US and proposed a 25 per cent levy on most goods from Mexico and Canada
Pfizer could move outside manufacturing to the US, says CEO
(Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the U.S., if required, as the Donald Trump administration threatens numerous tariffs on imported goods.
STAT11h
Pharmalittle: We’re reading about Pfizer navigating tariffs, Makary’s pledge to avoid conflicts, and more
Pfizer CEO Albert Bourla said the drugmaker might move overseas manufacturing to its plants in the U.S. as Trump threatens ...
FiercePharma11d
Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
Pfizer: Investors Won't Stick Around Forever
Pfizer may appeal to income investors, but growth prospects remain uncertain. Read why PFE stock might struggle to gain ...